Compare Alliant Energy Corporation (LNT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Alliant Energy Corporation trades at $65.88 (market cap $16.99B), while Regeneron Pharmaceuticals Inc trades at $745.91 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.5× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.27%). Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| LNT | REGN | |
|---|---|---|
Market Cap | $16.99B | $76.14B |
Volume | 2,488,387 | 500,239 |
Sector | Utilities | Health |
52-Week High | $78.03 | $852.03 |
52-Week Low | $63.21 | $557.73 |
Typical Hold Time | 64 Days | 107 Days |
Enterprise Value | $29.08B | $70.85B |
Dividend Yield | 3.27% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $65.84, up 0.97% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters and maintains solid profitability with an 18.45% net margin. Analyst consensus is bullish with a $77 price target, and institutional interest remains high, evidenced by recent large purchases.
LNT's outlook is supported by a $13.4 billion capital investment plan and growing data center demand, though rising debt levels and competitive pressures present risks. The stock offers a defensive income stream with a consistent dividend, but investors should monitor execution of growth initiatives amid economic uncertainty.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
